Table 2.

Reduction in SARS-CoV-2 lineages’ susceptibility to monoclonal antibodies based on pseudotyped virus-like particle neutralization assay

SARS-CoV-2 Lineage	World Health Organization Nomenclature	Casirivimab/Imdevimaba Reduction in Susceptibility	Bamlanivimab/Etesevimabb Reduction in Susceptibility	Sotrovimabc Reduction in Susceptibility	Tixagevimab/Cilgavimabd Reduction in Susceptibility	Bebtelovimabe Reduction in Susceptibility
B.1.1.7	Alpha	No change	No change	No change	0.5- to 5.2-fold	No change
B.1.351	Beta	No change	431-fold	No change	No change	No change
P.1	Gamma	No change	252-fold	No change	No change	No change
B.1.617.2/AY.3	Delta	No change	No change	No change	No change	No change
AY.1/AY.2 (B.1.617.2 sublineages)	Delta [+K417 N]	Not determined	1235-fold	No change	No change	No change
B.1.427/B.1.429	Epsilon	No change	9-fold	No change	No change	No change
B.1.526	Iota	No change	30-fold	No change	No change	No change
B.1.617.1	Kappa	No change	6-fold	No change	No change	No change
C.37	Lambda	Not determined	No change	No change	No change	No change
B.1.621	Mu	No change	116-fold	No change	7.5-fold	5.3-fold
B.1.1.529/BA.1	Omicron [BA.1]	>1013-fold	>2938-fold	No change	132- to 183-fold	No change
BA.1.1	Omicron [+R346 K]	Not determined	Not determined	No change	424-fold	No change
BA.2	Omicron [BA.2]	Not determined	Not determined	16-fold	No change	No change
BA.2.12.1	Omicron [BA.2 + L452Q]	Not determined	Not determined	Not determined	Not determined	No change
BA.4/BA.5	Omicron [BA.4/BA.5]	Not determined	Not determined	Not determined	No determined	No change

^aCasirivimab/imdevimab data from Food & Drug Administration (FDA) fact sheet⁴⁹ updated January 24, 2022.

^bBamlanivimab/etesevimab data from FDA fact sheet⁵¹ updated January 24, 2022.

^cSotrovimab data from FDA fact sheet⁵⁴ updated March 25, 2022.

^dTixagevimab/cilgavimab data from FDA fact sheet⁶⁰ updated May 17, 2022.

^eBebtelovimab data from FDA fact sheet⁵⁸ updated June 16, 2022.